What does “generic name” mean in a pharmaceutical context?
In the pharmaceutical industry, a “generic name” can mean one of two related but distinct things: it can refer to the International Nonproprietary Name (INN) — the standardized scientific name for an active ingredient — or it can refer to a post-patent generic drug, a manufacturer’s copy of a brand-name product sold under the INN rather than a proprietary name.
For semaglutide, the INN sense is the relevant one today. No post-patent generic version of semaglutide exists yet as of mid-2026. The branded products (Ozempic, Wegovy, Rybelsus) are still under patent protection. When patients search for “semaglutide generic names,” most are trying to understand this naming landscape — not looking for a patent-expired copycat product.
The INN: semaglutide as an active molecule
The World Health Organization’s International Nonproprietary Name programme assigns a single, universal scientific name to each active pharmaceutical ingredient. This name is used globally across scientific literature, regulatory filings, prescriptions, and compounding. It is the non-branded, non-proprietary identifier.
For this molecule, the INN is semaglutide. It describes a specific GLP-1 receptor agonist peptide with a defined amino acid sequence, modified with a C18 fatty acid chain that extends its half-life to allow once-weekly dosing. That is what semaglutide is, regardless of what brand name sits on the label.
What are the brand names for semaglutide and what is each approved for?
Novo Nordisk holds the patents on semaglutide and markets it under three brand names, each with its own FDA approval, dose range, and labeling:
Ozempic (semaglutide injection, 0.5 mg, 1 mg, 2 mg)
FDA-approved for improving glycemic control in adults with type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. Ozempic is a once-weekly subcutaneous injection. The maximum approved dose is 2 mg weekly.
Wegovy (semaglutide injection, 2.4 mg)
FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity. Wegovy contains semaglutide, like Ozempic, but at a higher maximum dose (2.4 mg weekly) under a different dose-escalation schedule. The two products are delivered in different pen devices.
Rybelsus (semaglutide tablets, 3 mg, 7 mg, 14 mg)
FDA-approved for improving glycemic control in adults with type 2 diabetes. This is the only oral formulation of semaglutide. It uses sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) as an absorption enhancer to protect the peptide from gastric degradation and enable absorption through the stomach lining. The oral route makes Rybelsus pharmacologically distinct from the injectable versions, though the active molecule is the same.
| Name | Type | FDA Indication | Max dose |
|---|---|---|---|
| Ozempic | Injectable (weekly) | Type 2 diabetes; CV risk reduction | 2 mg/week |
| Wegovy | Injectable (weekly) | Chronic weight management | 2.4 mg/week |
| Rybelsus | Oral tablet (daily) | Type 2 diabetes | 14 mg/day |
| Compounded semaglutide | Injectable (via 503A Rx) | Not FDA-approved; clinician Rx required | Per clinician protocol |
“Semaglutide” is the generic name — the single molecule behind Ozempic, Wegovy, and Rybelsus alike, no matter which brand sits on the label.
Compounded semaglutide: same molecule, different regulatory pathway
Compounded semaglutide occupies a distinct category from branded semaglutide products. It is not a generic — there is no FDA-approved generic — and it is not manufactured by Novo Nordisk. It is prepared by licensed 503A compounding pharmacies using pharmaceutical-grade semaglutide as the bulk drug substance, compounded under a physician’s prescription for an individual patient.
Key facts about compounded semaglutide:
- Not FDA-approved: No compounded medication carries FDA approval. The active ingredient is the same molecule, but the finished product has not been reviewed or approved by the FDA.
- Requires a prescription: A licensed clinician must evaluate the patient and issue a prescription. Compounded semaglutide cannot be purchased over the counter.
- 503A pharmacies: PepScribe connects patients with licensed 503A compounding pharmacies. 503A pharmacies compound for individual patient prescriptions. Compounded in the USA. No hidden overseas supply chain.
- Not bioequivalence-tested: Compounded semaglutide has not been through the bioequivalence testing that would qualify it as an FDA-approved generic. Efficacy and safety data from the branded semaglutide trials (using Novo Nordisk’s formulation) should not be assumed to apply identically to compounded versions.
When will a true generic semaglutide become available?
Patent timelines for pharmaceutical products are complex and subject to extension strategies. As a rough guideline, Novo Nordisk’s core semaglutide patents in the US are expected to begin expiring in the late 2020s to early 2030s, depending on the specific patent and any extensions. A post-patent generic would require a successful FDA Abbreviated New Drug Application (ANDA), which includes demonstrating bioequivalence to the branded reference product.
Multiple generic manufacturers have signaled interest in semaglutide. However, the timeline from patent expiration to generic market availability can take additional years due to manufacturing complexity, litigation, and approval timelines. The scale of global demand for semaglutide has made it one of the most closely watched future generic opportunities in the pharmaceutical industry.
Why does the naming distinction matter for patients?
Understanding the naming hierarchy helps patients evaluate what they are looking at when they encounter semaglutide across different contexts:
- When a clinician prescribes “semaglutide,” they are referring to the active ingredient. The specific product (branded vs. compounded, dose, delivery device) should be explicitly stated.
- When a telehealth service advertises “semaglutide,” it is almost certainly referring to compounded semaglutide — not branded Ozempic or Wegovy (which typically require insurance authorization and are dispensed through standard retail pharmacies). The distinction matters for understanding what you are getting.
- Claims that compounded semaglutide is interchangeable with branded Ozempic or Wegovy are accurate only in that the molecule shares the same INN. But the formulation, manufacturing standards, quality controls, and regulatory oversight differ. A transparent provider will acknowledge this distinction.
Learn more about how PepScribe’s clinician-supervised compounded semaglutide program works.
Frequently asked questions
What is the generic name for semaglutide?
"Semaglutide" is the generic name — specifically, the International Nonproprietary Name (INN) assigned by the World Health Organization. Brand names include Ozempic (for type 2 diabetes), Wegovy (for weight management), and Rybelsus (oral tablet for type 2 diabetes), all manufactured by Novo Nordisk.
Is there a generic version of Ozempic or Wegovy?
As of mid-2026, no FDA-approved generic version of Ozempic or Wegovy is available. The branded products are still under patent. Compounded semaglutide, prepared by licensed 503A pharmacies, is a different access pathway — not an FDA-approved generic, but the same active molecule.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide as the active ingredient. The differences are dose range and FDA-approved indication. Ozempic is approved for type 2 diabetes management, at doses up to 2 mg weekly. Wegovy is approved for weight management in adults with obesity or overweight plus a weight-related condition, at a maximum dose of 2.4 mg weekly.
Is compounded semaglutide the same as Ozempic?
Compounded semaglutide uses the same active molecule (semaglutide) but is prepared by a licensed 503A compounding pharmacy rather than manufactured by Novo Nordisk. It is not FDA-approved and is not bioequivalence-tested against Ozempic. The compounded formulation is prescribed by a licensed clinician based on an individual patient assessment.
What does INN mean in the context of semaglutide?
INN stands for International Nonproprietary Name — the official non-branded name assigned to an active pharmaceutical ingredient by the World Health Organization. "Semaglutide" is the INN. Brand names like Ozempic and Wegovy are proprietary commercial names used by Novo Nordisk for its specific formulations.
What is Rybelsus?
Rybelsus is an oral tablet formulation of semaglutide, also manufactured by Novo Nordisk. It is FDA-approved for type 2 diabetes management. Unlike Ozempic and Wegovy (which are injectable), Rybelsus is taken by mouth daily. It uses a different delivery mechanism (the SNAC absorption enhancer) to allow the peptide to survive digestion.